Joseph E Rower1, Eric G Meissner2, Leah C Jimmerson1, Anu Osinusi3, Zayani Sims2, Tess Petersen2, Lane R Bushman1, Pamela Wolfe4, John G McHutchison5, Shyamasundaran Kottilil2, Jennifer J Kiser6. 1. Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, CO, USA. 2. Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, NIAID, Bethesda, MD, USA. 3. Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, NIAID, Bethesda, MD, USA Gilead Sciences Inc., Foster City, CA, USA. 4. School of Public Health, University of Colorado, Aurora, CO, USA. 5. Gilead Sciences Inc., Foster City, CA, USA. 6. Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, CO, USA jennifer.kiser@ucdenver.edu.
Abstract
OBJECTIVES:Ribavirin concentrations may impact hepatitis C virus (HCV) treatment outcome. We modelled ribavirin serum and intracellular ribavirin monophosphate (RBV-MP) and ribavirin triphosphate (RBV-TP) pharmacokinetics in red blood cells (RBC) using samples collected during the NIAID SPARE trial to explore associations with treatment outcome and the development of anaemia. PATIENTS AND METHODS: Individuals infected with HCV genotype 1 (GT1) received 400 mg of sofosbuvir and either low-dose or weight-based ribavirin as part of the NIAID SPARE trial. Concentrations were modelled using NONMEM and associated with treatment outcomes using unpaired t-tests or Pearson's rho correlations. RESULTS:Average day 14 RBV-MP concentrations were higher in subjects with haemoglobin nadir <10 g/dL relative to patients with haemoglobin nadir ≥10 g/dL (6.54 versus 4.48 pmol/10(6) cells; P = 0.02). Additionally, day 14 RBV-MP average concentrations trended towards being higher in subjects that achieved sustained virological response (SVR) as compared with patients who relapsed (4.97 versus 4.09 pmol/10(6) cells; P = 0.07). Receiver operating characteristic curves suggested day 14 RBV-MP concentration thresholds of 4.4 pmol/10(6) cells for SVR (P = 0.06) and 6.1 pmol/10(6) cells for haemoglobin nadir <10 versus ≥10 g/dL (P = 0.02), with sensitivity and specificity ≥60%. Dosing simulations showed that 800 mg of ribavirin once daily produced day 14 RBV-MP concentrations within the 4.4-6.1 pmol/10(6) cells range. CONCLUSIONS:RBV-MP concentrations in RBC at day 14 were related to anaemia and SVR. A therapeutic range was identified for RBV-MP in persons with HCV GT1 disease receiving 24 weeks of sofosbuvir plusribavirin, suggesting a potential pharmacological basis for individualized ribavirin dosing in IFN-free regimens.
RCT Entities:
OBJECTIVES:Ribavirin concentrations may impact hepatitis C virus (HCV) treatment outcome. We modelled ribavirin serum and intracellular ribavirin monophosphate (RBV-MP) and ribavirin triphosphate (RBV-TP) pharmacokinetics in red blood cells (RBC) using samples collected during the NIAID SPARE trial to explore associations with treatment outcome and the development of anaemia. PATIENTS AND METHODS: Individuals infected with HCV genotype 1 (GT1) received 400 mg of sofosbuvir and either low-dose or weight-based ribavirin as part of the NIAID SPARE trial. Concentrations were modelled using NONMEM and associated with treatment outcomes using unpaired t-tests or Pearson's rho correlations. RESULTS: Average day 14 RBV-MP concentrations were higher in subjects with haemoglobin nadir <10 g/dL relative to patients with haemoglobin nadir ≥10 g/dL (6.54 versus 4.48 pmol/10(6) cells; P = 0.02). Additionally, day 14 RBV-MP average concentrations trended towards being higher in subjects that achieved sustained virological response (SVR) as compared with patients who relapsed (4.97 versus 4.09 pmol/10(6) cells; P = 0.07). Receiver operating characteristic curves suggested day 14 RBV-MP concentration thresholds of 4.4 pmol/10(6) cells for SVR (P = 0.06) and 6.1 pmol/10(6) cells for haemoglobin nadir <10 versus ≥10 g/dL (P = 0.02), with sensitivity and specificity ≥60%. Dosing simulations showed that 800 mg of ribavirin once daily produced day 14 RBV-MP concentrations within the 4.4-6.1 pmol/10(6) cells range. CONCLUSIONS:RBV-MP concentrations in RBC at day 14 were related to anaemia and SVR. A therapeutic range was identified for RBV-MP in persons with HCV GT1 disease receiving 24 weeks of sofosbuvir plus ribavirin, suggesting a potential pharmacological basis for individualized ribavirin dosing in IFN-free regimens.
Authors: Antonio DʼAvolio; Alessia Ciancio; Marco Siccardi; Antonina Smedile; Lorena Baietto; Marco Simiele; Diego Aguilar Marucco; Giuseppe Cariti; Andrea Calcagno; Daniel Gonzalez de Requena; Mauro Sciandra; Jessica Cusato; Giulia Troshina; Stefano Bonora; Mario Rizzetto; Giovanni Di Perri Journal: Ther Drug Monit Date: 2012-04 Impact factor: 3.681
Authors: Michael P Curry; Xavier Forns; Raymond T Chung; Norah A Terrault; Robert Brown; Jonathan M Fenkel; Fredric Gordon; Jacqueline O'Leary; Alexander Kuo; Thomas Schiano; Gregory Everson; Eugene Schiff; Alex Befeler; Edward Gane; Sammy Saab; John G McHutchison; G Mani Subramanian; William T Symonds; Jill Denning; Lindsay McNair; Sarah Arterburn; Evguenia Svarovskaia; Dilip Moonka; Nezam Afdhal Journal: Gastroenterology Date: 2014-09-28 Impact factor: 22.682
Authors: Alexander J Thompson; Jacques Fellay; Keyur Patel; Hans L Tillmann; Susanna Naggie; Dongliang Ge; Thomas J Urban; Kevin V Shianna; Andrew J Muir; Michael W Fried; Nezam H Afdhal; David B Goldstein; John G McHutchison Journal: Gastroenterology Date: 2010-06-12 Impact factor: 22.682
Authors: Antonio D'Avolio; Amedeo De Nicolò; Marco Simiele; Stefano Turini; Danilo Agnesod; Lucio Boglione; Jessica Cusato; Lorena Baietto; Giuseppe Cariti; Andrea Calcagno; Mauro Sciandra; Giovanni Di Perri; Stefano Bonora Journal: J Pharm Biomed Anal Date: 2012-03-28 Impact factor: 3.935
Authors: Runyan Jin; Ling Cai; Ming Tan; John G McHutchison; Thomas C Dowling; Charles D Howell Journal: Am J Gastroenterol Date: 2012-10-23 Impact factor: 10.864
Authors: Eric Lawitz; Mark S Sulkowski; Reem Ghalib; Maribel Rodriguez-Torres; Zobair M Younossi; Ana Corregidor; Edwin DeJesus; Brian Pearlman; Mordechai Rabinovitz; Norman Gitlin; Joseph K Lim; Paul J Pockros; John D Scott; Bart Fevery; Tom Lambrecht; Sivi Ouwerkerk-Mahadevan; Katleen Callewaert; William T Symonds; Gaston Picchio; Karen L Lindsay; Maria Beumont; Ira M Jacobson Journal: Lancet Date: 2014-07-28 Impact factor: 79.321
Authors: Edward J Fuchs; Jennifer J Kiser; Craig W Hendrix; Mark Sulkowski; Christine Radebaugh; Lane Bushman; Michelle L Ray; Adriana Andrade Journal: J Antimicrob Chemother Date: 2016-02-10 Impact factor: 5.790
Authors: Darius Babusis; Michael P Curry; Brian Kirby; Yeojin Park; Eisuke Murakami; Ting Wang; Anita Mathias; Nezam Afdhal; John G McHutchison; Adrian S Ray Journal: Antimicrob Agents Chemother Date: 2018-04-26 Impact factor: 5.191
Authors: Susanna Naggie; Kristen M Marks; Michael Hughes; Daniel S Fierer; Christine Macbrayne; Arthur Kim; Kimberly Hollabaugh; Jhoanna Roa; Bill Symonds; Diana M Brainard; John G McHutchison; Marion G Peters; Jennifer J Kiser; Raymond Chung Journal: Clin Infect Dis Date: 2017-04-15 Impact factor: 9.079
Authors: Christine E MacBrayne; Kristen M Marks; Daniel S Fierer; Susanna Naggie; Raymond T Chung; Michael D Hughes; Arthur Y Kim; Marion G Peters; Diana M Brainard; Sharon M Seifert; Jose R Castillo-Mancilla; Lane R Bushman; Peter L Anderson; Jennifer J Kiser Journal: J Antimicrob Chemother Date: 2018-08-01 Impact factor: 5.790